Here's Wouldn't Touch This: Why I Won't Invest Now in EVTOL Darling
The eVTOL craze mixes hype with real engineering, regulatory hurdles, and capital burn. Here's why I wouldn't touch t...
A concise guide to retirement funds with the lowest fees, detailing how fees affect compounding and overall retirement outcomes.
27,102 articlesThe eVTOL craze mixes hype with real engineering, regulatory hurdles, and capital burn. Here's why I wouldn't touch t...
JPMorgan Chase is tightening its lending standards for private deals while a $33 billion private credit fund faces he...
Bitcoin hovered near the $60,000 mark but briefly slid toward $58,000 as ETF outflows intensified and inflation data ...
Regulators have signaled close scrutiny of a possible Paramount-Warner Bros. merger, threatening delays and potential...
Investors are racing to price in the first real revenue opportunities from quantum tech as a new federal funding push...
A major fund recently trimmed its stake in Viridian Therapeutics, signaling potential rotation rather than a verdict ...
Rivian priced a 75 million share secondary offering, sending its stock down around 14% and triggering a market-wide p...
As Turning Point Brands rode a wave of rising oral nicotine sales, one fund made a bold move: trimming a multi-millio...
BonkDAO’s governance proposal drained roughly $20 million in BONK from its treasury, underscoring a new risk surface ...
A niche nuclear tech stock reported solid revenue gains, but a large fund reduced its holdings. Learn how to read the...
The idea that skilled trades could become high earners is reshaping how investors view AI-driven growth. This piece c...
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...